Abstract
Magnesium deficiency is suggested to contribute to many age-related diseases. Hypoxia-inducible factor 1α (HIF-1α) is known to be a master regulator of hypoxic response. Here we show that hypomagnesemia suppresses reactive oxygen species (ROS)-induced HIF-1α activity in paraganglion cells of the adrenal medulla and carotid body. In PC12 cells cultured in the low magnesium medium and treated with cobalt chloride (CoCl2) or exposed to intermittent hypoxia, ROS-mediated HIF-1α activity was suppressed. This suppression was due to up-regulation of inhibitory PAS (Per/Arnt/Sim) domain protein (IPAS) that was caused by NF-κB activation, which resulted from ROS and calcium influx mainly through the T-type calcium channels. Induction of tyrosine hydroxylase, a target of HIF-1, by CoCl2 injection was suppressed in the adrenal medulla of magnesium-deficient mice because of up-regulation of IPAS. Also in the carotid body of magnesium-deficient mice, CoCl2 and chronic intermittent hypoxia failed to enhance the tyrosine hydroxylase expression. These results demonstrate that serum magnesium levels are a key determinant for ROS-induced hypoxic responses.
Hypoxia-inducible factor 1α (HIF-1α)2 and its family members are master regulators of hypoxic response (1–3). In hypoxia, the HIF-1, composed of HIF-1α and HIF-1β/Arnt, binds to hypoxia response element (HRE) to induce the gene expression of hypoxia-responsive proteins, such as erythropoietin and vascular endothelial growth factor. In addition to these proteins, tyrosine hydroxylase (TH), the rate-limiting enzyme for catecholamine biosynthesis, is induced in rat pheochromocytoma-derived PC12 cells and paraganglion cells in the adrenal medulla (AM) and carotid body (CB) in response to hypoxia (4). The CB acts as the primary peripheral chemoreceptor (5), and glomus cells of the CB are responsible for monitoring oxygen levels in arterial blood (5, 6). Through the release of neurotransmitters, including dopamine, the CB delivers information to the respiratory and cardiovascular networks in the brainstem, resulting in increases of ventilatory frequency and volume and also raising cardiac output.
HIF-dependent hypoxic response is also caused by chronic intermittent hypoxia (CIH), which is a common feature of obstructive sleep apnea (OSA). There is accumulating evidence that CIH is associated with an increased oxidative stress (7, 8). Peng et al. (9) have shown that CIH induces reactive oxygen species (ROS) generation, thereby increasing HIF-1α expression, which is critical for eliciting CIH-induced cardiorespiratory responses by the CB. CIH also increases ROS generation and TH expression in the AM, although it is less sensitive than the CB (10).
Recent studies have identified that IPAS, which is one of the alternatively spliced variants of HIF-3α, acts as a dominant negative inhibitor of HIF-1α by a direct interaction with HIF-1α and prevents its DNA binding (11). IPAS is predominantly expressed in the Purkinje cells of the cerebellum and corneal epithelium. In addition, because the IPAS gene has an HRE sequence in its promoter, IPAS can be induced by hypoxia in the heart and lung. Therefore, IPAS acts as a negative feedback inhibitor of HIF-1α (12).
Magnesium deficiency is believed to be related to many diseases, such as hypertension, ischemic heart disease, and diabetes mellitus (13–16). However, the molecular mechanisms underlying the role of magnesium in the pathogenesis of these diseases have been largely undefined. Our analyses here demonstrate that magnesium deficiency causes a loss of ROS-induced HIF-1α activity by inducing IPAS gene expression.
EXPERIMENTAL PROCEDURES
Cell Culture, DNA Transfection, and IH Treatment
PC12, Hep3B, C6, and B16-f10 cells were obtained from the Cell Resource Center for Biomedical Research of Tohoku University. PC12 cells were maintained in RPMI 1640 (Wako Pure Chemical Industries) supplemented with 10% fetal bovine serum in collagen IV-coated dishes (BD Biosciences) under 5% CO2 at 37 °C and transferred every 3 days. Transfection was performed using the lipofection reagent (TransFast; Promega) according to the manufacturer's protocol. The change of RPMI to DMEM (Wako Pure Chemical Industries) was performed 1 day before transfection experiments, and cells were transfected in serum-free DMEM. After the cells were incubated for 1 h, each appropriate medium was added, and the cells were treated with 100 μm cobalt chloride (CoCl2) for 10 h. The growth rate of PC12 cells in the two media was similar (data not shown). IH treatment was carried out as follows. 1.5 h after transfection, the cells were exposed to 54 cycles of 15 s in duration at 4.5% O2 followed by 2 min at 21% O2, approximately seven episodes/h, 8 h/day with 10% CO2 in an O2/CO2 incubator (Wakenyaku, Co., Ltd). The cells exposed to room air with 10% CO2 (normoxia) in a CO2 incubator served as controls. Hep3B, B16-f10, and C6 cells were grown in DMEM, RPMI, and RPMI, respectively, with 10% fetal bovine serum. Hep3B and C6 cells were transfected by the calcium-phosphate precipitation method. B16-f10 cells were transfected by Lipofectamine 2000 (Invitrogen). Construction of the HRE-dependent luciferase reporter plasmid and the assay of luciferase activity were described previously (17). Data from PC12 and B16-f10 cells were normalized to the concentration of protein. E1b-luciferase 2 (E1b-luc2) with five copies of NF-κB response element plasmid (NF-κB REx5-E1b-luc2) was constructed by inserting five copies of the sequence (5′-GGGAATTTCC-3′) between the BglII site and NheI of the E1b-luc2 plasmid. The dual luciferase reporter assay was performed according to the manufacturer's protocol (Promega).
Drug Treatments
Drugs were purchased as follows: MK-801, nifedipine, sulfasalazine, NF-κB SN50 cell-permeable inhibitor peptide, cyclosporin A, and rottlerin were from Calbiochem; NAC, mibefradil, BMS-345541, and PMA were from Sigma-Aldrich; LY294002 was from Cell Signaling Technology; cilnidipine was from BIOMOL International LP; and A23187 was from Wako Pure Chemical Industries. The cells were treated with each drug 30 min before 100 μm CoCl2 treatment.
Measuring Calcium Concentration
Calcium levels in the cells were determined using the fluorescent probe Fluo-8 AM (ABD Bioquest, Inc.). PC12 cells were cultured in a collagen IV-coated 35-mm glass-bottomed dish. The growth medium was removed, and the cells were incubated with 2.5 μm Fluo-8 AM, 10% Pluronic F-127 (ABD Bioquest, Inc.), 250 mm probenecid (Invitrogen), and 20 mm Hepes in Hanks' balanced salt solution (Invitrogen) at 37 °C, 5% CO2 incubator for 30 min. The cells were washed with phosphate-buffered saline and then incubated in serum-free, phenol red-free DMEM or RPMI for 30 min with 50 ng/ml Hoechst 33342. After incubation, the cells were treated with CoCl2 for 5 min and imaged with a fluorescence microscope (Olympus IX71). PC12 cells were treated with 8 μg/ml A23187 as controls.
Animals
Male C57BL/6J Jms Slc mice (∼16 weeks of age) were randomly divided into two groups, with each group having a similar mean body weight, and fed on a magnesium-deficient diet (AIN-93 M diet, Low-Mg, Nihon Nosan Kogyo Co., Japan) or a normal diet (AIN-93 M diet, standard) for 14 days in a 12-h light and 12-h dark cycle at 23 °C. The magnesium-deficient diet and the normal diet contained 0.0004% and 0.0844% magnesium, respectively. A dose of 60 μg of CoCl2·6H2O or saline/g of body weight was administered intraperitoneally. In the case of CIH, the mice were randomly divided into two groups; the mice in each group had similar mean body weights, but one group was fed on the magnesium-deficient diet, whereas the other had been fed on the normal diet for 3 weeks. The mice were exposed to CIH (54 cycles consisting of 15 s at 6% O2 followed by 5 min at 21% O2, approximately seven episodes/h, 8 h/day) for the last 2 weeks in the O2/CO2 incubator (Wakenyaku, Co., Ltd). Mice exposed to room air of 21% O2 (normoxia) served as controls. Serum magnesium levels were determined colorimetrically using the Wako Magnesium B test kit (Wako Pure Chemical Industries). Animal care and use were reviewed and approved by the Committee for Animal Research of Tohoku University.
Western Blotting
Nuclear extracts or cell lysate were prepared from PC12 cells and Hep3B cells as described previously (17). The proteins were extracted from the adrenal gland using the extraction reagent (T-PER; Pierce). A total of 35 μg (from cells) or 15 μg (from mice) of protein was loaded on an 8% SDS-polyacrylamide gel. HIF-1α, TH, and IκB-α were detected using the ECL Western kit (GE Healthcare). The anti-TH antibody was a generous gift from Dr. I. Nagatsu. The anti-HIF-1α monoclonal antibody and an anti-IκB-α monoclonal antibody were purchased from Novus Biologicals and Cell Signaling Technology, respectively.
RT-PCR
Total RNA was extracted from cultured cells or adrenal glands using RNA isolating reagent (RNAiso; Takara Bio). cDNAs were synthesized using oligonucleotide random hexamers (Takara Bio) and Moloney murine leukemia virus reverse transcriptase (Invitrogen). A fraction (1 μl) of synthesized cDNA was amplified in a 20-μl reaction mixture containing 5 units of Taq polymerase (Ex TaqHS; Takara Bio). PCR cycles were chosen within the linear range of amplification. The PCR procedure consisted of 20 cycles of reaction for 18 S rRNA cDNA, 21 for β-actin, 21 for TH, 28 for HIF-1α-like factor, 30 for HIF-1α, 33 for HIF-3α, 35 for VHL and IPAS: 94 °C for 30 s, 60 °C for 30 s, and 72 °C for 30 s. The bands were quantified by using Image J software. For amplification of mouse IPAS, we employed 33 cycles of reaction: 96 °C for 15 s and 68 °C for 1 min using KOD-Plus-polymerase (Toyobo), and the PCR products were electrophoresed on 6% polyacrylamide gels and quantified on an Imaging analyzer (Fuji BAS1000). The primers used for the reaction are described in supplemental Table S2. For rat IPAS primers, the rat IPAS putative exon 16 sequence was found by homology search in the NCBI data base.
siRNA
RNA oligonucleotides (21 nucleotides) homologous to HIF-3α/IPAS were designed as follows: forward, 5′-GCUCA UUGGA CACAG UAUCT T, and reverse, 5′-GAUAC UGUGU CCAAU GAGCT T; and control siRNA homologous to green fluorescent protein sequence, forward, 5′-GGCUA CGUCC AGGAG CGCAT T, and reverse, 5′-UGCGC UCCUG GACGU AGCCT T. The cells were treated with annealed siRNAs using Oligofectamine (Invitrogen) according to the manufacturer's protocol. After 24 h, the change of RPMI to DMEM was carried out. Subsequent transfection was performed as described above.
In Situ Hybridization
The adrenal gland and CB were fixed in neutral buffered formalin (Mildform10N; Wako Pure Chemical Industries) at 4 °C overnight, dehydrated in an ethanol series, embedded in paraffin, and cut into 8-μm sections. Tissue sections were deparaffinized in xylene and rehydrated in a graded series of ethanol. Subsequently, sections of the adrenal gland and CB were treated with 1 μg/ml proteinase K (Roche Applied Science) in phosphate-buffered saline at room temperature for 12 and 5 min, respectively, and the sections of the adrenal gland were acetylated. Hybridization was carried out in a solution containing 50% formamide, 2× SSC, 1 μg/μl tRNA, 1 μg/μl salmon sperm DNA, 1 μg/μl bovine serum albumin, 10% dextran sulfate, and digoxigenin-linked cRNA probes for 18 h at 55 °C. Digoxigenin-linked cRNA probes for TH mRNA (nucleotides 1139–1525) were synthesized by T7 (antisense) or T3 (sense) RNA polymerase using a pBlueScript SK(+)-based template. The samples were treated with an anti-digoxigenin antibody conjugated with alkaline phosphate (Roche Applied Science) in 1:100 dilution for 30 min at room temperature and subsequently reacted with 330 μg/ml NBT, 165 μg/ml 5-bromo-4-chloro-3-indolyl phosphate, and 1 mm levamisole for 18 h at room temperature. It was counterstained with the nuclear dye, kernechtrot (red) (Muto Pure Chemicals).
Immunohistochemistry
The samples were prepared similarly as mentioned above. All of the sections were treated for 30 min with 3% hydrogen peroxide in methanol to quench endogenous peroxidase activity. An antibody against TH was used as the first antibody in dilution 1:100,000. A secondary antibody reaction was carried out using horseradish peroxidase-linked anti-rabbit goat IgG at room temperature for 1 h. The samples were subsequently reacted with 3,3′-diaminobenzidine and counterstained with the nuclear dye, kernechtrot (red) or hematoxylin (dark blue).
Statistical Analysis
The data are given as the means ± standard deviation, with the number of the experiments indicated. Statistical significance was established by paired Student's t tests. In experiments using the adrenal gland (see Fig. 4, B and D), statistical significance was established by unpaired Student's t tests.
RESULTS
Loss of Hypoxic Response Induced by CoCl2 in RPMI-cultured PC12 Cells
To examine the hypoxic response of PC12 cells in different nutritional conditions, we introduced a reporter plasmid containing HREs (Fig. 1A) (17) and treated with CoCl2, a chemical mimetic of hypoxia. In DMEM-cultured PC12 cells, a 4-fold induction of reporter activity was found in response to CoCl2 (Fig. 1B). However, in the RPMI 1640 medium (RPMI), no increase in luciferase activity was observed (Fig. 1B). When human hepatoma Hep3B cells, mouse melanoma B16-F10 cells and rat glioma C6 cells were used, the hypoxic response was observed in both DMEM and RPMI (Fig. 1B and supplemental Fig. S1), indicating that the medium dependence was cell type-specific. We attempted to identify the causal nutrients for the loss of HIF transactivation activity. Medium-specific nutrients were examined, but they exhibited no effect on the distinct hypoxic response (supplemental Fig. S1 and supplemental Table S1, groups 1 and 6). Because almost all the common nutrients included were richer in DMEM than in RPMI, we divided the nutrients into four groups (supplemental Table S1, groups 2–5), added excess amounts of grouped nutrients to RPMI and assayed the reporter activity (supplemental Fig. S1). Subsequently, each nutrient in the positive groups was tested (supplemental Fig. S1). Consequently, three nutrients, magnesium, histidine, and threonine, were identified. In PC12 cells cultured in RPMI that contained these three nutrients at concentrations equivalent to those in DMEM, the CoCl2-induced hypoxic response was recovered (Fig. 1C). The addition of each nutrient to RPMI yielded hypoxic responsibility in a dose-dependent manner (Fig. 1D). We examined the possibility that HIF-1α protein stability was decreased in RPMI-cultured PC12 cells. However, the nuclear HIF-1α protein was stabilized by the treatment of CoCl2 in both DMEM and RPMI media (Fig. 1E). The addition of the three nutrients to RPMI had no effect on the stabilization of HIF-1α.
IPAS Is Responsible for Suppression of Hypoxic Response
We investigated the possibility that IPAS is involved in the nutrient-dependent hypoxic response. As expected, IPAS mRNA was significantly induced in response to CoCl2 only when PC12 cells were cultured in RPMI (Fig. 2A). The addition of a mixture of magnesium, His, and Thr to RPMI inhibited the induction of IPAS mRNA, and the inducible expression of the TH gene was recovered (Fig. 2A). The expression levels of HIF-1α, HIF-1α-like factor (also known as HIF-2α or EPAS1), and VHL mRNAs remained unchanged in PC12 cells regardless of the culture media and whether they were treated with CoCl2 (supplemental Fig. S2). HIF-3α mRNA was very weakly expressed in PC12 cells cultured in both media and was apparently not affected by the presence of CoCl2. The overexpression of IPAS apparently inhibited HRE-dependent reporter activity, although its inhibition was incomplete even when large amounts of the IPAS expression plasmid were used (Fig. 2B). The endogenous IPAS mRNA level was decreased by IPAS/HIF-3α siRNA treatment (Fig. 2C). The siRNA treatment recovered the induction of TH mRNA by CoCl2 in RPMI-cultured PC12 cells. Furthermore, induction of reporter activity was also recovered to some extent by the suppression of IPAS expression (Fig. 2D). HIF-3α mRNA was very weakly expressed, and we were unable to detect a down-regulation of the expression by the treatment (supplemental Fig. S2).
Activation of the ROS-PI3K Pathway by CoCl2 and Intermittent Hypoxia in PC12 Cells
We examined whether the loss of HIF activity in RPMI is observed when PC12 cells were treated by sustained hypoxia. The inducible expression of luciferase activity was caused by hypoxia in both DMEM and RPMI (Fig. 3A), suggesting different mechanisms leading to hypoxic response of the cells between hypoxia and CoCl2. To examine whether the ROS-phosphatidylinositol 3-kinase (PI3K) pathway is involved in the induction of HIF-1α by CoCl2, we used a ROS scavenger, NAC, and a PI3K inhibitor, LY294002. When treated with NAC, the up-regulation of luciferase activity was impaired in a dose-dependent manner (Fig. 3B). Moreover, CoCl2 failed to induce HIF-1α activity in DMEM and IPAS mRNA in RPMI when treated with LY294002 (Fig. 3C). These results suggest that HIF-1α is induced by CoCl2 via the ROS-PI3K pathway.
To examine the cellular response to IH, PC12 cells were exposed either to 21% O2 (normoxia) or to 54 cycles of IH. TH mRNA was weakly but reproducibly induced by IH in PC12 cells cultured in DMEM, but not in RPMI (Fig. 3D and supplemental Fig. S3). The addition of the three nutrients to RPMI recovered the inducibility of TH mRNA. IPAS mRNA was induced only in RPMI-cultured PC12 cells in response to IH. Moreover, an approximate 1.5-fold induction of luciferase activity was found in DMEM-cultured PC12 cells in response to IH (Fig. 3E). On the other hand, the induction was modest in the cells grown in RPMI but was recovered when the three nutrients were added to RPMI. Furthermore, inducible luciferase activity in DMEM caused by IH was inhibited by NAC (Fig. 3F). Collectively, these results demonstrate that the induction of HIF-1α activity by IH as well as CoCl2 is ROS-dependent and suggest that IPAS induced by IH is responsible for the inhibition of the ROS-mediated HIF-1α activity.
Hypomagnesemia Suppresses Response to CoCl2 and CIH in the AM and CB
We hypothesized that suppression of the hypoxic response caused by a deficiency of the nutrients might also occur in vivo. We focused on magnesium as a deficient nutrient because magnesium deficiency is known to be involved in many age-related diseases, and its serum level is relatively easily controlled by diet. Because PC12 cells were derived from the AM, the hypoxic response in the AM of mice with hypomagnesemia was investigated. Fig. 4A shows that serum magnesium levels were gradually decreased in mice fed on a magnesium-deficient diet. In 2 weeks, serum magnesium levels of mice fed on a magnesium-deficient diet were decreased to ∼40% of control mice, and they were used for analysis of hypoxia-related gene expression by RT-PCR. TH mRNA was induced in the adrenal gland of normal mice by the injection of CoCl2, but not in magnesium-deficient mice (Fig. 4B). IPAS mRNA was weakly (2.0-fold) induced in normal mice by the injection of CoCl2. In contrast, a strong induction (6.0-fold) was observed in CoCl2-injected magnesium-deficient mice. HIF-1α, HIF-1α-like factor, and HIF-3α mRNAs were relatively evenly expressed in the mice regardless of their diets or whether they had been injected with CoCl2 (supplemental Fig. S4). Moreover, in situ hybridization experiments showed that TH mRNA was induced in the AM of CoCl2-injected normal mice but not at all in magnesium-deficient mice (Fig. 4C). Western blotting (Fig. 4D) and immunostaining assays (Fig. 4E) have shown that TH protein was up-regulated in normal mice but not in magnesium-deficient mice by CoCl2 injection.
We investigated the hypoxic response of CB in mice with magnesium deficiency. In situ hybridization assays showed that TH expression in the CB was increased in CoCl2-injected normal mice but not in magnesium-deficient mice (Fig. 5A). Immunostaining assays also showed that TH protein levels in the CB were enhanced in CoCl2-injected normal mice but not in magnesium-deficient mice (Fig. 5B).
We next examined whether the loss of TH up-regulation is observed in magnesium-deficient mice exposed to CIH (Fig. 6A). As expected, in situ hybridization experiments (Fig. 6B) and immunostaining assays (Fig. 6C) clearly showed that both TH mRNA and protein were increased in CIH-exposed normal mice but not at all in magnesium-deficient mice. The response to CIH in the adrenal gland was also investigated. However, TH in the AM was not induced in normal mice under the CIH conditions used in this study,3 confirming previous results that the AM is less sensitive to CIH than the CB (10). Further extensive exposure of mice to CIH is necessary to clarify the inducibility of TH expression in the AM.
Molecular Mechanism Leading to IPAS Gene Activation
We investigated the mechanism that results in activation of the IPAS gene in PC12 cells. Because magnesium acts as a calcium antagonist at multiple voltage-gated channels (18), their involvement was investigated. As shown in Fig. 7A, an increase in the intracellular calcium level was observed 5 min after CoCl2 treatment of PC12 cells cultured in RPMI but not in DMEM. A pharmacological calcium channel blocker, mibefradil, which inhibits T-type channels and also weakly inhibits L-type channels (19), inhibited the induction of IPAS mRNA and activated reporter activity in response to CoCl2 (Fig. 7B). NiCl2, which is a specific inhibitor of the T-type calcium channels (20) and also a chemical mimetic of hypoxia like CoCl2 (2), inhibited the activation of the IPAS gene and activated reporter activity in RPMI-cultured PC12 cells (Fig. 7C). The addition of MK-801, an N-methyl-d-aspartate receptor antagonist, weakly activated the reporter activity in response to CoCl2 (Fig. 7D). Nifedipine and cilnidipine, L-type channel-specific and both L-type and N-type channel-specific blockers, respectively, were of no effect.3 Treatment of cells with calcium ionophore, A23187, induced expression of IPAS mRNA in response to CoCl2 treatment and inactivated HRE-dependent reporter activity (Fig. 7E). These results suggest that calcium influx mainly through the T-type calcium channels is involved in the ROS-dependent IPAS gene expression in PC12 cells cultured in RPMI.
An increase in intracellular calcium levels possibly activates several transcription factors such as NF-κB, CREB, and NFAT. We tested several inhibitors for the canonical NF-κB pathway. Sulfasalazine (an IKK inhibitor) and BMS-345541 (a specific inhibitor of IKKβ and weak inhibitor of IKKα) blocked induction of IPAS and enhanced reporter activity in response to CoCl2 in RPMI (Fig. 8A). SN50, a peptide inhibitor for nuclear translocation of NF-κB, also inhibited IPAS expression and activated reporter activity (Fig. 8A). There was also a weak decrease of IκB-α at 15 min after CoCl2 treatment in RPMI-cultured PC12 cells (Fig. 8B). NF-κB-dependent reporter activity in the RPMI-cultured PC12 cells was induced by CoCl2 (Fig. 8B). These results indicate that increased calcium levels result in activation of NF-κB. PMA, an activator of conventional and novel PKC isotypes (21), inhibited induction of HRE reporter activity, and enhanced IPAS expression regardless of CoCl2 treatment (Fig. 8C). An activator of CREB, dibutyryl cAMP, was of no effect, and a CRE reporter was not activated by CoCl2.3 Cyclosporin A, inhibitor of calcineurin, which is a protein phosphatase and activates NFAT, activated neither IPAS gene expression nor HRE-dependent reporter activity in response to CoCl2 in RPMI (supplemental Fig. S5).
DISCUSSION
Previous studies have shown that HIF-1α in normoxia is hydroxylated by prolyl hydroxylases in an O2 and Fe2+-dependent manner and recognized by pVHL, leading to degradation. It is therefore generally accepted that prolyl hydroxylase activity is inhibited by sustained hypoxia and by Co2+ that can substitute active-site Fe2+ (22). However, recent reports have shown that the induction of HIF-1α by CoCl2 is dependent on ROS and PI3K signaling-mediated protein translation (23, 24). CoCl2 activates the PI3K pathway by ROS generation, and PI3K-Akt enhances the translation of cellular mRNAs, including HIF-1α mRNA. The results from a present study are in good accordance with the conclusion from the latter studies that CoCl2 acts as a ROS generator, leading to activation of PI3K.
In human, ROS-dependent hypoxic response is caused by OSA. OSA, characterized by CIH, was shown to cause hypertension (25, 26) and is associated with an increased risk of cardiovascular disease (27, 28). The mechanisms underlying the development of cardiovascular disease in patients with OSA syndromes are poorly understood. The most likely hypothesis is that of a multifactorial process including sympathetic overactivity, selective activation of inflammatory pathways, endothelial dysfunction, and metabolic dysregulation (28). In addition to OSA, ROS-dependent hypoxic response is generated after ischemia-reperfusion that occurs in the treatment of myocardial infarction and stroke. It is accepted that HIF activation confers protection against ischemia-reperfusion injury (29, 30). Although ROS is also generated in various pathological conditions, including hyperglycemia caused by type I and II diabetes (31), it is undefined whether HIF-α up-regulation is associated with increased ROS levels.
Magnesium deficiency is not a rare occurrence and is seen in ∼2% of the general population. It is common in patients with diabetes mellitus and alcoholism. It is also common in critically ill patients in intensive care unit settings with a reported prevalence ranging from ∼20 to 65% (16). In patients with ischemic heart disease, magnesium deficiency is also frequently found, and this has been reported to be directly related to the disease (13, 15). The present study strongly suggests that magnesium deficiency, which attenuates ROS-dependent hypoxic response, may be a risk factor for the patients suffering from ROS-related diseases such as OSA and ischemia-reperfusion injury, and it could promote the development of complications of the diseases. Magnesium deficiency and ROS have been separately considered to have roles in the etiology of ischemic cardiovascular diseases and ischemic stroke. Our results demonstrate that there is a close linkage between these two pathogenic factors. The mechanism that HIF-1 activity is regulated by extracellular His and Thr is unknown and awaited for clarification.
The present study also suggests that expression of T-type calcium channels may, at least in part, define cell type specificity of magnesium-dependent hypoxic responsibility (Fig. 1B). T-type channels are expressed in several types of excitable cells including neurons in the central and peripheral nervous system, cardiac and smooth muscle cells, and chromaffin cells (19, 32). T-type channels in the nervous system are implicated in the generation of absence seizures, sleep modulation, and pain perception (33, 34), and in cardiac cells they are suggested to be important for cardiac conduction and pacemaking (32). Although T-type channels are also expressed in nonexcitable cells such as vascular endothelial cells, fibroblasts, and cancer cells (32), functions in those cells are largely unknown. T-type channels can be activated by a weak depolarization near the resting membrane potential. There are three genes for the pore-forming α1 subunit of T-type channels, CACNA1G for α1G, CACNA1H for α1H, and CACNA1I for α1I. These three α1 subunits are expressed differently or concomitantly in various cells (19, 32). It remains to be seen which subunit(s) is responsible for the magnesium-dependent calcium influx. It is interesting to note that the α1H subunit is induced by hypoxia (35).
The present study demonstrates that suppression of ROS-induced hypoxic response may occur in the cells expressing T-type calcium channels such as paraganglion cells in the AM (36) and CB (37). Loss of hypoxic response at the gene level and possible inappropriate activation of the NF-κB target genes in the cells may cause an unwanted and unexpected response, leading to their deteriorate functions. NF-κB activates a variety of genes for immune response, cell adhesion, stress response, cell survival, and oncogenesis (38). In PC12 cells, cooperation of two different signals, one from calcium entry and the other from PI3K, was necessary for NF-κB activation. Activation of IPAS gene expression by the treatment of PMA suggests that PKC is involved in the activation process. An analogous mechanism for NF-κB activation has been known in antigen-stimulated T and B cells (39). In T cells activated by antigen-presenting cells, NF-κB is fully stimulated by two different signals, one from activated T cell receptors binding to antigen and major histocompatibility complex (signal 1) and the other from costimulatory molecules such as CD28 (signal 2). CD28 costimulation mediates up-regulation of PI3K and successively PDK1, which modulates signals through T cell receptors and leads to different cell fates (40, 41). These two signals fully activate PKCθ, which in turn activates CARMA1 to form the CARMA complex (CARMA1, Bcl10, and MALT1), allowing activation of IKK (21, 40, 42). In B cell activation, PKCβ is involved instead of PKCθ. Because of extreme sensitivity of PC12 cells to pharmacological inhibitors of PKC, we are presently unable to identify PKC isotypes that are involved in the up-regulation of NF-κB, although an inhibitor of PKCθ, rottlerin, suppressed the IPAS mRNA induction (supplemental Fig. S5). It is important to know the detailed molecular mechanism by which IKK is activated in PC12 cells and paraganglion cells. Constitutive expression of IPAS was reported in the Purkinje cells of the cerebellum and corneal epithelial cells (11), and reports demonstrated its inducible expression by hypoxia, creating a negative feedback loop(12). Present study demonstrates that its expression is up-regulated by NF-κB, leading to suppression of HIF-1 activity in at least paraganglion cells under low magnesium environment.
Supplementary Material
Acknowledgments
We are grateful to Dr. Y. Makino and Dr. I. Nagatsu for the gift of mouse IPAS cDNA and the antibody to TH, respectively. We also thank Dr. A. Igarashi (Yamagata Prefectural Shinjo Hospital), Dr. H. Ohta (Tohoku University Hospital), and Dr. H. Yawo (Tohoku University) for helpful discussions and Y. Sato, T. Ishizawa, and S. Murakami for technical assistance.
This work was supported in part by a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan.
The on-line version of this article (available at http://www.jbc.org) contains supplemental Tables S1 and S2 and Figs. S1–S5.
S. Torii, K. Kobayashi, M. Takahashi, K. Katahira, K. Goryo, N. Matsushita, K.-I. Yasumoto, Y. Fujii-Kuriyama, and K. Sogawa, unpublished data.
- HIF
- hypoxia-inducible factor
- ROS
- reactive oxygen species
- TH
- tyrosine hydroxylase
- HRE
- hypoxia response element
- AM
- adrenal medulla
- CB
- carotid body
- IH
- intermittent hypoxia
- CIH
- chronic IH
- OSA
- obstructive sleep apnea
- PAS
- Per/Arnt/Sim
- IPAS
- inhibitory PAS domain protein
- DMEM
- Dulbecco's modified Eagle's medium
- PMA
- phorbol 12-myristate 13-acetate
- NAC
- N-acetyl-l-cysteine
- RT
- reverse transcription
- siRNA
- small interfering RNA
- PI3K
- phosphatidylinositol 3-kinase
- PKC
- protein kinase C.
REFERENCES
- 1.Hirota K., Semenza G. L. (2005) Biochem. Biophys. Res. Commun. 338, 610–616 [DOI] [PubMed] [Google Scholar]
- 2.Schofield C. J., Ratcliffe P. J. (2005) Biochem. Biophys. Res. Commun. 338, 617–626 [DOI] [PubMed] [Google Scholar]
- 3.Kaelin W. G., Jr. (2005) Biochem. Biophys. Res. Commun. 338, 627–638 [DOI] [PubMed] [Google Scholar]
- 4.Paulding W. R., Schnell P. O., Bauer A. L., Striet J. B., Nash J. A., Kuznetsova A. V., Czyzyk-Krzeska M. F. (2002) Microsc. Res. Tech. 59, 178–187 [DOI] [PubMed] [Google Scholar]
- 5.Peers C., Buckler K. J. (1995) J. Membr. Biol. 144, 1–9 [DOI] [PubMed] [Google Scholar]
- 6.Pardal R., Ortega-Sáenz P., Durán R., López-Barneo J. (2007) Cell 131, 364–377 [DOI] [PubMed] [Google Scholar]
- 7.Xu W., Chi L., Row B. W., Xu R., Ke Y., Xu B., Luo C., Kheirandish L., Gozal D., Liu R. (2004) Neuroscience 126, 313–323 [DOI] [PubMed] [Google Scholar]
- 8.Chen L., Einbinder E., Zhang Q., Hasday J., Balke C. W., Scharf S. M. (2005) Am. J. Respir. Crit. Care Med. 172, 915–920 [DOI] [PubMed] [Google Scholar]
- 9.Peng Y. J., Yuan G., Ramakrishnan D., Sharma S. D., Bosch-Marce M., Kumar G. K., Semenza G. L., Prabhakar N. R. (2006) J. Physiol. 577, 705–716 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Hui A. S., Striet J. B., Gudelsky G., Soukhova G. K., Gozal E., Beitner-Johnson D., Guo S. Z., Sachleben L. R., Jr., Haycock J. W., Gozal D., Czyzyk-Krzeska M. F. (2003) Hypertension 42, 1130–1136 [DOI] [PubMed] [Google Scholar]
- 11.Makino Y., Cao R., Svensson K., Bertilsson G., Asman M., Tanaka H., Cao Y., Berkenstam A., Poellinger L. (2001) Nature 414, 550–554 [DOI] [PubMed] [Google Scholar]
- 12.Makino Y., Uenishi R., Okamoto K., Isoe T., Hosono O., Tanaka H., Kanopka A., Poellinger L., Haneda M., Morimoto C. (2007) J. Biol. Chem. 282, 14073–14082 [DOI] [PubMed] [Google Scholar]
- 13.Turlapaty P. D., Altura B. M. (1980) Science 208, 198–200 [DOI] [PubMed] [Google Scholar]
- 14.Altura B. M., Altura B. T., Gebrewold A., Ising H., Günther T. (1984) Science 223, 1315–1317 [DOI] [PubMed] [Google Scholar]
- 15.Rude R. K. (1998) J. Bone Miner Res. 13, 749–758 [DOI] [PubMed] [Google Scholar]
- 16.Tong G. M., Rude R. K. (2005) J. Intensive Care Med. 20, 3–17 [DOI] [PubMed] [Google Scholar]
- 17.Sogawa K., Numayama-Tsuruta K., Ema M., Abe M., Abe H., Fujii-Kuriyama Y. (1998) Proc. Natl. Acad. Sci. U.S.A. 95, 7368–7373 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Delpiano M. A., Altura B. M. (1996) FEBS Lett. 394, 335–339 [DOI] [PubMed] [Google Scholar]
- 19.Perez-Reyes E. (2003) Physiol. Rev. 83, 117–161 [DOI] [PubMed] [Google Scholar]
- 20.Lee J. H., Gomora J. C., Cribbs L. L., Perez-Reyes E. (1999) Biophys. J. 77, 3034–3042 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Spitaler M., Cantrell D. A. (2004) Nat. Immunol. 5, 785–790 [DOI] [PubMed] [Google Scholar]
- 22.Ke Q., Costa M. (2006) Mol. Pharmacol. 70, 1469–1480 [DOI] [PubMed] [Google Scholar]
- 23.Chachami G., Simos G., Hatziefthimiou A., Bonanou S., Molyvdas P. A., Paraskeva E. (2004) Am. J. Respir. Cell Mol. Biol. 31, 544–551 [DOI] [PubMed] [Google Scholar]
- 24.Griguer C. E., Oliva C. R., Kelley E. E., Giles G. I., Lancaster J. R., Jr., Gillespie G. Y. (2006) Cancer Res. 66, 2257–2263 [DOI] [PubMed] [Google Scholar]
- 25.Nieto F. J., Young T. B., Lind B. K., Shahar E., Samet J. M., Redline S., D'Agostino R. B., Newman A. B., Lebowitz M. D., Pickering T. G. (2000) Jama 283, 1829–1836 [DOI] [PubMed] [Google Scholar]
- 26.Peppard P. E., Young T., Palta M., Skatrud J. (2000) N. Engl. J. Med. 342, 1378–1384 [DOI] [PubMed] [Google Scholar]
- 27.Shamsuzzaman A. S., Gersh B. J., Somers V. K. (2003) Jama 290, 1906–1914 [DOI] [PubMed] [Google Scholar]
- 28.Parati G., Lombardi C., Narkiewicz K. (2007) Am. J. Physiol. Regul. Integr. Comp. Physiol. 293, R1671–1683 [DOI] [PubMed] [Google Scholar]
- 29.Natarajan R., Salloum F. N., Fisher B. J., Kukreja R. C., Fowler A. A., 3rd (2006) Circ. Res. 98, 133–140 [DOI] [PubMed] [Google Scholar]
- 30.Loor G., Schumacker P. T. (2008) Cell Death Differ. 15, 686–690 [DOI] [PubMed] [Google Scholar]
- 31.Ha H., Hwang I. A., Park J. H., Lee H. B. (2008) Diabetes Res. Clin. Pract. 82, S42–S45 [DOI] [PubMed] [Google Scholar]
- 32.Yunker A. M., McEnery M. W. (2003) J. Bioenerg. Biomembr. 35, 533–575 [DOI] [PubMed] [Google Scholar]
- 33.Bourinet E., Alloui A., Monteil A., Barrère C., Couette B., Poirot O., Pages A., McRory J., Snutch T. P., Eschalier A., Nargeot J. (2005) EMBO J. 24, 315–324 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Shin H. S., Cheong E. J., Choi S., Lee J., Na H. S. (2008) Curr. Opin. Pharmacol. 8, 33–41 [DOI] [PubMed] [Google Scholar]
- 35.Del Toro R., Levitsky K. L., López-Barneo J., Chiara M. D. (2003) J. Biol. Chem. 278, 22316–22324 [DOI] [PubMed] [Google Scholar]
- 36.Vinet R., Vargas F. F. (1999) Am. J. Physiol. 276, H1313–H1322 [DOI] [PubMed] [Google Scholar]
- 37.Caceres A. I., Gonzalez-Obeso E., Obeso A., Gonzalez C., Rocher A. (2007) Acta Physiol. 190, (suppl.) 655 [Google Scholar]
- 38.Pahl H. L. (1999) Oncogene 18, 6853–6866 [DOI] [PubMed] [Google Scholar]
- 39.Schmitz M. L., Bacher S., Dienz O. (2003) FASEB J. 17, 2187–2193 [DOI] [PubMed] [Google Scholar]
- 40.Lee K. Y., D'Acquisto F., Hayden M. S., Shim J. H., Ghosh S. (2005) Science 308, 114–118 [DOI] [PubMed] [Google Scholar]
- 41.Parry R. V., Riley J. L., Ward S. G. (2007) Trends Immunol. 28, 161–168 [DOI] [PubMed] [Google Scholar]
- 42.Springael C., Thomas S., Rahmouni S., Vandamme A., Goldman M., Willems F., Vosters O. (2007) Biochem. Pharmacol. 73, 515–525 [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.